Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Vaxcyte

Rank#2219

Market Cap8.81B

CountryUnited States

Summary

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

History

Vaxcyte was founded in 2018, combining the pioneering spirit of innovation, unyielding commitment to science, and drive to help prevent, control and manage life-threatening infectious diseases.

Mission

To develop and deliver vaccines, treatments and cures that benefit humankind worldwide.

Vision

Vaxcyte’s vision is to be a world leader in the prevention, control and management of life-threatening infectious diseases.

References

https://in.investing.com/equities/vaxcyte-inc

https://finance.yahoo.com/quote/PCVX/profile?p=PCVX

https://www.crunchbase.com/organization/sutrovax

https://sec.report/CIK/0001649094

https://companiesmarketcap.com/

https://vaxcyte.com

Leadership team

Mr. Grant E. Pickering M.B.A. (Co-Founder, CEO & Director)

Mr. Andrew L. Guggenhime M.B.A. (Pres, CFO & Principal Accounting Officer)

Mr. James Wassil M.B.A., M.S. (Exec. VP & COO)

Products / Services

Biopharma, Biotechnology, Health Care

Number of Employees

50 - 100

Address

San Carlos, California, United States

Established

2013-01-01

Company Registration

SEC CIK number: 0001649094

Traded as

PCVX

Website

https://vaxcyte.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Vaxcyte

Rank#2219

Market Cap8.81B

CountryUnited States

Summary

History

Vaxcyte was founded in 2018, combining the pioneering spirit of innovation, unyielding commitment to science, and drive to help prevent, control and manage life-threatening infectious diseases.

Mission

To develop and deliver vaccines, treatments and cures that benefit humankind worldwide.

Vision

Vaxcyte’s vision is to be a world leader in the prevention, control and management of life-threatening infectious diseases.

References

https://in.investing.com/equities/vaxcyte-inc

https://finance.yahoo.com/quote/PCVX/profile?p=PCVX

https://www.crunchbase.com/organization/sutrovax

https://sec.report/CIK/0001649094

https://companiesmarketcap.com/

https://vaxcyte.com

Leadership team